Pharmaceutical Technology
FEBRUARY 26, 2023
In the last decade, the idea of tapping into the gut has attracted much interest from investors and the public, but recent years have showed that a lot more work needs to be done before such treatments enter the mainstream.
Bio Pharma Dive
FEBRUARY 27, 2023
Celgene veteran Scott Smith will take over for Michael Goettler on April 1 as the generic drugmaker prepares for a return to growth after divestitures and the addition of a new eye care division
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
MARCH 3, 2023
Annual Drug Patent Expirations for NORMOCARB+HF+25 Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA. There is one patent protecting this drug.
Pharma Phorum
FEBRUARY 27, 2023
Engaging digitally native healthcare professionals requires companies to challenge existing business ethos and commit to the customer experience in an increasingly digital world. Life Sciences" HCP Digital
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Pharmaceutical Technology
MARCH 2, 2023
The US Food and Drug Administration (FDA) has approved Reata Pharmaceuticals ’ oral, once-daily medication SKYCLARYS (omaveloxolone) to treat Friedreich’s ataxia patients.
Bio Pharma Dive
MARCH 1, 2023
At a time when many startups have struggled to gain cash, the biotech has raised another $135 million to back its research, a new twist on genetic medicine
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
FEBRUARY 28, 2023
FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv kdunleavy Tue, 02/28/2023 - 18:55
Pharmaceutical Technology
MARCH 2, 2023
Merck has reported an increase in group net sales by 12.9% to €22.23bn in fiscal 2022 against €19.68bn in 2021. The growth in sales was driven by all regions and business sectors, particularly Life Science. Organically, the company generated an increase of 6.4% in group sales in fiscal 2022.
Bio Pharma Dive
FEBRUARY 28, 2023
The biotech said the FDA was unconvinced by available study evidence and asked for data from an additional clinical trial, which the company currently does not plan to run
FDA Law Blog
MARCH 2, 2023
By Charles D. Snow — As Benjamin Franklin once ( apocryphally ) stated: “Beer is proof that God loves us and wants us to be happy.” And what comes with such a heaven-sent, nourishing beverage? Mainly hangovers and beer bellies, but also fierce marketplace competition and gamesmanship.
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Pharma Times
FEBRUARY 28, 2023
Research into modified RNA messages could help treat diseases and develop new therapies
Pharmaceutical Technology
MARCH 1, 2023
The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi ’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients.
Bio Pharma Dive
MARCH 2, 2023
The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst
Fierce Pharma
MARCH 1, 2023
Eli Lilly slashes insulin prices by 70%, caps out-of-pocket costs in major access overhaul fkansteiner Wed, 03/01/2023 - 08:40
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Pharma Times
MARCH 3, 2023
Treatment is a lung-specific stem cell therapy designed for hospitalised patients with respiratory infections
Pharmaceutical Technology
FEBRUARY 28, 2023
Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs.
Bio Pharma Dive
FEBRUARY 28, 2023
Aptinyx has joined a lengthy list of drugmakers looking to cut costs and explore strategic options after hitting setbacks in key clinical studies
Fierce Pharma
MARCH 1, 2023
Pfizer, Viatris and more must face 'overarching conspiracy' claims in generic price-fixing suit aliu Wed, 03/01/2023 - 10:03
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Pharma Times
FEBRUARY 27, 2023
If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU
Pharmaceutical Technology
MARCH 2, 2023
On 1 March, the FDA issued the International Council for Harmonisation (ICH) final guidance on the use of continuous manufacturing in drug production.
Bio Pharma Dive
MARCH 3, 2023
An experimental medicine from Praxis Precision Medicines missed the main goal of a Phase 2b trial. But there were also some positive findings, which have encouraged the company to press forward
Drug Patent Watch
FEBRUARY 25, 2023
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Serbia?
Pharma Times
MARCH 3, 2023
Extensive phase 1 clinical trial evaluates safety of treatment among peritoneal patients
Pharmaceutical Technology
FEBRUARY 28, 2023
The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) continues to increase, compounded by risk factors such as advanced age, obesity, ethnicity, and type 2 diabetes mellitus (T2DM).
Bio Pharma Dive
MARCH 1, 2023
The pharma company, along with its diabetes drug rivals Novo Nordisk and Sanofi, has long been under pressure over the high cost of insulin — scrutiny that has recently ramped up in the U.S.
BioSpace
FEBRUARY 26, 2023
After Historic Hemophilia B Approval, uniQure Targets Huntington’s and ALS 2/27/2023
Pharma Times
MARCH 2, 2023
European Medicines Agency has issued a positive opinion for the use of VLA2001 among certain adults
Pharmaceutical Technology
MARCH 1, 2023
Venture financing for early-stage innovator drugs for biotech companies based in the Asia-Pacific (APAC) region between 2018 to 2022 received three times less funding, at $23bn, than their US counterparts, at $72bn, according to GlobalData’s Pharma Intelligence Centre Deals Database.
Bio Pharma Dive
FEBRUARY 27, 2023
Citing people familiar with the talks, The Wall Street Journal reported over the weekend that Pfizer is trying to acquire Seagen and its suite of cancer therapies in a deal that could be worth more than $30 billion
Fierce Pharma
MARCH 3, 2023
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices kdunleavy Fri, 03/03/2023 - 10:38
Pharma Times
FEBRUARY 27, 2023
Tech was created to overcome adoption obstacles currently reducing the use of predictive human liver models
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Bio Pharma Dive
FEBRUARY 28, 2023
An alliance with the startup brings Vertex an RNA-based medicine for the disease, adding to a portfolio that already includes a gene editing treatment
Expert insights. Personalized for you.
278 
Let's personalize your content